Skip to main content
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology

Open Access 07-05-2025 | Positron Emission Tomography | short review

A short review on the current status of PSMA ligands used for PSMA-PET/CT imaging

Authors: Dr. med. Lilit Schweiger, Irene Virgolini

Published in: memo - Magazine of European Medical Oncology

Login to get access

Summary

In recent years, prostate-specific membrane antigen (PSMA)-targeted positron emission tomography/computed tomography (PET/CT) imaging has had substantial impact on the management of prostate cancer (PCa) patients. PSMA is both an ideal target for diagnostic and therapeutic applications in men with PCa. PSMA-ligand PET/CT imaging has become a reference imaging tool for the detection and localization of recurrent disease in patients with biochemical failure after curative treatment, as well as detecting metastases in advanced stages of PCa, but has also gained importance in the primary diagnosis and staging of PCa. The aim of this short review is to reflect the latest developments in the use of PSMA-PET/CT imaging as well as outline possible challenges and limitations of this new molecular imaging modality.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
A short review on the current status of PSMA ligands used for PSMA-PET/CT imaging
Authors
Dr. med. Lilit Schweiger
Irene Virgolini
Publication date
07-05-2025
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-025-01043-6

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Incorporating comprehensive genomic profiling into the standard-of-care for NSCLC and thyroid cancer

In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.

This content is intended only for US-based healthcare providers.

Supported by:
  • Illumina, Inc., and Eli Lilly and Company
Dr. Vivek Subbiah
Dr. Alexander Drilon
Dr. Michelle Williams
Developed by: Springer Healthcare
Watch now
Video

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more
Image Credits